Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
BioVie Inc. logo

NASDAQ · BIVI

BioVie Inc.

Healthcare · Biotechnology

$1.73

Down-$0.41 (-23.70%)

Updated Nov 4, 2026, 5:02 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.46M
P/E ratio
-0.43
Dividend yield
0.00%
52-week range
$0.82 – $3.79
Volume
13.54M
Avg. volume
141.08K

Price performance · BIVI

BIVI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

BIVI closed at $1.73 after 21 trading sessions, up 20.14% for the selected period.

Last close
$1.73
Period change
+20.14%
Period low
$1.13
Period high
$1.73
Daily close
View OHLC price history
BIVI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.45$2.66$1.40$1.7313.54M
Nov 2, 2026$1.41$1.43$1.31$1.37120.89K
Oct 30, 2026$1.39$1.49$1.38$1.43105.82K
Oct 29, 2026$1.43$1.46$1.37$1.3841.87K
Oct 28, 2026$1.49$1.49$1.4123$1.46106.75K
Oct 27, 2026$1.37$1.45$1.34$1.44196.23K
Oct 26, 2026$1.25$1.36$1.25$1.33146.57K
Oct 23, 2026$1.28$1.30$1.23$1.24141.65K
Oct 22, 2026$1.24$1.29$1.215$1.28101.05K
Oct 21, 2026$1.21$1.2766$1.15$1.26195.07K
Oct 20, 2026$1.40$1.45$1.24$1.24279.51K
Oct 19, 2026$1.29$1.39$1.2036$1.37182.52K
Oct 16, 2026$1.13$1.22$1.12$1.20275.93K
Oct 15, 2026$1.18$1.19$1.13$1.13166.88K
Oct 14, 2026$1.20$1.25$1.15$1.16342.64K
Oct 13, 2026$1.30$1.3312$1.20$1.20171.97K
Oct 12, 2026$1.41$1.4412$1.31$1.3267.35K
Oct 9, 2026$1.30$1.40$1.275$1.39204.86K
Oct 8, 2026$1.37$1.39$1.25$1.28362.16K
Oct 7, 2026$1.46$1.47$1.40$1.40134.62K
Oct 6, 2026$1.44$1.50$1.44$1.44132.71K

Latest BIVI news

The latest Smart Investors Daily articles mentioning BIVI.

Stock researchCompany · Overview

BIVI research

Overview

Company profile and research snapshot.

Company profile

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BIVI recent ratings
DateFirmRatingTarget
Jul 1, 2024ThinkEquityBuy—
Nov 30, 2023OppenheimerOutperform—
Aug 22, 2023Cantor FitzgeraldOverweight—
Jul 18, 2023Cantor FitzgeraldOverweight—
May 17, 2023Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop

CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop, hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and the Foundation for the National Institutes of Health (FNIH) from November

Yahoo · Oct 20, 2026

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological...

Yahoo · Oct 20, 2026

BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting

Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct. 20, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of results from the Phase 2 SUNRISE-PD clinical trial evaluating bezi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By